Study On Capital Operation Risk Of A Pharmaceutical Company

Under the background of an aging population, China’s pharmaceutical enterprises to usher in better opportunities for development, many brands long history, strong competitive pharmaceutical companies also stand out. But overall, China’s pharmaceutical companies are still showing a higher total enterprises, small average size of the situation. Plus foreign pharmaceutical products in the domestic market share to compete for market competition in the domestic pharmaceutical industry is extremely competitive, foreign pharmaceutical research and development capabilities, high production efficiency, large-scale, rich marketing tool, domestic pharmaceutical enterprises are facing technical and marketing management the dual pressures of respect. Thus, the domestic pharmaceutical enterprises are facing tough market conditions and higher operational risks. In order to stay competitive in a complex external conditions, many of the pharmaceutical companies want to operate through the capital to promote the successful transformation of their own development strategies and management, and hopes to increase research and development and marketing and other ways to seek new impetus to the development. But pharmaceutical companies of different scale, high barriers to entry, supply chain more complex, while capital recovery cycle is relatively long. At present, China nearly 7,000 pharmaceutical enterprises, large-scale management of large enterprise fewer than 400, the majority of enterprises are faced with excess capacity, weak research and development and other issues, companies need to re-planning its own development strategy, through capital operation model will be digested and reduce external risks, in order to achieve a successful transition. In the current competitive landscape of the pharmaceutical industry, pharmaceutical companies have emerged to improve the degree of concentration trends, the pace of merger and reorganization within the industry to accelerate capital works will become an important means for business transformation and pattern of planning. However, the risk capital operation during diverse and complex business operation in the capital only to do comprehensive risk response measures will be developed in order to minimize risk, the smooth realization of the transformation operations.This article is A pharmaceutical company as capital to operational risk management cases objects, analyze its capital risk management and control in the transition development. A pharmaceutical companies to bring about restructuring and development of enterprises through a series of capital operation in the current market environment. In the course of its capital operation, integrated use of the investment expansion strategy, multi-channel financing strategy, low-cost strategy, steady cash flow strategy and external cooperation strategy; we encountered investment risk, investment risk, operational risk, market risk, policy risk and risk of drug quality and many other risks, these risks and take the appropriate control measures, such as optimize capital structure, strengthen the management level management team, risk control sales and accounts receivable risk management and strengthening marketing. We hope this study can provide some reference and help for the prevention and control of operational risk capital pharmaceutical companies, which in turn promote the sound and healthy development of China’s pharmaceutical enterprises to promote their forest among the world pharmaceutical industry.